FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization

Thumbnail
2016
2549.pdf (939.9Kb)
Authors
Petrova, Guenka
Benbassat, Boriana
Lakić, Dragana
Dimitrova, Maria
Mitov, Konstantin
Dimitrov, Josif
Article (Published version)
Metadata
Show full item record
Abstract
The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted prob...ability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.

Source:
Biotechnology & Biotechnological Equipment, 2016, 30, 3, 614-621
Publisher:
  • Taylor & Francis Ltd, Abingdon

DOI: 10.1080/13102818.2016.1160796

ISSN: 1310-2818

WoS: 000376259700026

Scopus: 2-s2.0-84978381211
[ Google Scholar ]
3
3
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2551
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Petrova, Guenka
AU  - Benbassat, Boriana
AU  - Lakić, Dragana
AU  - Dimitrova, Maria
AU  - Mitov, Konstantin
AU  - Dimitrov, Josif
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2551
AB  - The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Biotechnology & Biotechnological Equipment
T1  - Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization
VL  - 30
IS  - 3
SP  - 614
EP  - 621
DO  - 10.1080/13102818.2016.1160796
ER  - 
@article{
author = "Petrova, Guenka and Benbassat, Boriana and Lakić, Dragana and Dimitrova, Maria and Mitov, Konstantin and Dimitrov, Josif",
year = "2016",
abstract = "The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Biotechnology & Biotechnological Equipment",
title = "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization",
volume = "30",
number = "3",
pages = "614-621",
doi = "10.1080/13102818.2016.1160796"
}
Petrova, G., Benbassat, B., Lakić, D., Dimitrova, M., Mitov, K.,& Dimitrov, J.. (2016). Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment
Taylor & Francis Ltd, Abingdon., 30(3), 614-621.
https://doi.org/10.1080/13102818.2016.1160796
Petrova G, Benbassat B, Lakić D, Dimitrova M, Mitov K, Dimitrov J. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment. 2016;30(3):614-621.
doi:10.1080/13102818.2016.1160796 .
Petrova, Guenka, Benbassat, Boriana, Lakić, Dragana, Dimitrova, Maria, Mitov, Konstantin, Dimitrov, Josif, "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization" in Biotechnology & Biotechnological Equipment, 30, no. 3 (2016):614-621,
https://doi.org/10.1080/13102818.2016.1160796 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB